Answers are grounded in this paper and cite their sources.
Demonstrates IL-4 and IL-13 roles in bullous pemphigoid, suggesting dupilumab as a treatment.
Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a clinically debilitating immune-related adverse event in need of novel therapeutic approaches, as conventional treatment can counteract intended tumour immunity. Here we demonstrate that interleukin (IL)-4 and IL-13 expression is elevated in ICI-BP similar to conventional autoimmune BP, and further demonstrate partial and complete disease clearance with dupilumab in four patients with ICI-BP. These data indicate that IL-4Rα inhibition may be a promising new therapy for ICI-BP.
No takes yet. Share an insight, caveat, or question.
Shipman et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: